A Phase 2 interventional study of PRT064445/Enoxaparin and Placebo/Enoxaparin in Healthy Volunteers, sponsored by Portola Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-22.
Sponsored by Portola Pharmaceuticals (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
A randomized, double-blind, vehicle-controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously administered PRT064445 after dosing to steady state with one of four direct/indirect factor Xa (fXa) inhibitors in healthy volunteers.
Portola Pharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.
First submitted before Portola Pharmaceuticals became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
210 mg PRT064445 given as a single IV bolus
Combination Product: PRT064445/Enoxaparin · Combination Product: Placebo/Enoxaparin
420 mg PRT064445 given as a single IV bolus
Combination Product: PRT064445/Enoxaparin · Combination Product: Placebo/Enoxaparin
210 mg PRT064445 (lyophilized formulation) given as a single IV bolus
Combination Product: PRT064445/Enoxaparin · Combination Product: Placebo/Enoxaparin
Placebo administered intravenously (IV) as a bolus.
Drug: Placebo
Drug pages: PRT064445 · Enoxaparin
Also known as: Andexanet
Efficacy:Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration Activity
Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma)
Time frame: Baseline to 2 minutes following the end of andexanet/placebo administration
Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration
Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay.
Time frame: Baseline to 2 minutes following the end of andexanet/placebo administration
Andexanet Maximum Observed Plasma Concentration (Cmax)
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Cmax was taken directly from the raw data.
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Andexanet Time of Maximum Observed Plasma Concentration (Tmax)
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data.
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Andexanet Apparent Terminal Elimination Half-life (t1/2)
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay.t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve.
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Andexanet Total Systemic Clearance (CL)
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach.
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Andexanet Total Volume of Distribution (Vss)
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach.
Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Subject recruitment occurred at investigative site in the US between August 2013 through November 2013
| Milestone | Placebo | Module 3 (210 mg Bolus) Original | Module 3 (420 mg Bolus) Original | Module 3 (210 mg) Lyophilized |
|---|---|---|---|---|
| Started | 9 | 6 | 6 | 6 |
| Completed | 8 | 6 | 6 | 6 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma)
| Percent change in anti-fXa activity | Placebo | Module 3 (210 mg Bolus) Original | Module 3 (420 mg Bolus) Original | Module 3 (210 mg) Lyophilized |
|---|---|---|---|---|
| Efficacy:Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration Activity | -3.57 ± 12.80 | -70.80 ± 6.98 | -60.83 ± 8.39 | -69.85 ± 7.46 |
Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay.
| Percent change in thrombin generation | Placebo | Module 3 (210 mg Bolus) Original | Module 3 (420 mg Bolus) Original | Module 3 (210 mg) Lyophilized |
|---|---|---|---|---|
| Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration | 3.48 ± 15.162 | 36.34 ± 15.127 | 107.48 ± 73.301 | 72.7 ± 74.301 |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Cmax was taken directly from the raw data.
| ng/mL | Placebo | Module 3 (210 mg Bolus) Original | Module 3 (420 mg Bolus) Original | Module 3 (210 mg) Lyophilized |
|---|---|---|---|---|
| Andexanet Maximum Observed Plasma Concentration (Cmax) | — | 32000 ± 7320 | 55800 ± 6050 | 42700 ± 14400 |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach
| ng*hr/mL | Placebo | Module 3 (210 mg Bolus) Original | Module 3 (420 mg Bolus) Original | Module 3 (210 mg) Lyophilized |
|---|---|---|---|---|
| Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf ) | — | 33600 ± 4280 | 63900 ± 8880 | 40900 ± 12300 |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data.
| hr | Placebo | Module 3 (210 mg Bolus) Original | Module 3 (420 mg Bolus) Original | Module 3 (210 mg) Lyophilized |
|---|---|---|---|---|
| Andexanet Time of Maximum Observed Plasma Concentration (Tmax) | — | 0.18 (0.16 to 0.35) | 0.29 (0.27 to 0.54) | 0.17 (0.17 to 0.19) |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay.t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve.
| hr | Placebo | Module 3 (210 mg Bolus) Original | Module 3 (420 mg Bolus) Original | Module 3 (210 mg) Lyophilized |
|---|---|---|---|---|
| Andexanet Apparent Terminal Elimination Half-life (t1/2) | — | 5.28 ± 1.99 | 6.11 ± 2.34 | 8.36 ± 7.46 |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach.
| L/hr | Placebo | Module 3 (210 mg Bolus) Original | Module 3 (420 mg Bolus) Original | Module 3 (210 mg) Lyophilized |
|---|---|---|---|---|
| Andexanet Total Systemic Clearance (CL) | — | 6.34 ± 0.870 | 6.69 ± 0.991 | 5.56 ± 1.76 |
Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach.
| L | Placebo | Module 3 (210 mg Bolus) Original | Module 3 (420 mg Bolus) Original | Module 3 (210 mg) Lyophilized |
|---|---|---|---|---|
| Andexanet Total Volume of Distribution (Vss) | — | 9.86 ± 2.61 | 9.62 ± 1.13 | 9.69 ± 4.16 |
Collected over ~7 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/8 (0%) | 5/8 (62.5%) |
| Module 3 (210 mg Andexanet) Original Formulation | — | 0/6 (0%) | 4/6 (66.7%) |
| Module 3 (420 mg Andexanet) Original Forumulation | — | 0/6 (0%) | 4/6 (66.7%) |
| Module 3 (210 mg Andexanet ) Lyophilized | — | 0/6 (0%) | 5/6 (83.3%) |
| Event | Placebo | Module 3 (210 mg Andexanet) Original Formulation | Module 3 (420 mg Andexanet) Original Forumulation | Module 3 (210 mg Andexanet ) Lyophilized |
|---|---|---|---|---|
| Abdominal tendernessGastrointestinal disorders | 3/8 | 0/6 | 0/6 | 0/6 |
| Dry mouthGastrointestinal disorders | 0/8 | 0/6 | 2/6 | 0/6 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/8 | 1/6 | 1/6 | 2/6 |
| Procedural site reactionInjury, poisoning and procedural complications | 2/8 | 1/6 | 2/6 | 1/6 |
| DizzinessNervous system disorders | 0/8 | 0/6 | 2/6 | 0/6 |
| Procedural painInjury, poisoning and procedural complications | 2/8 | 1/6 | 1/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/8 | 0/6 | 0/6 | 1/6 |
| DyspepsiaGastrointestinal disorders | 0/8 | 0/6 | 1/6 | 0/6 |
| NauseaGastrointestinal disorders | 1/8 | 0/6 | 1/6 | 1/6 |
| ToothacheGastrointestinal disorders | 0/8 | 0/6 | 1/6 | 0/6 |
27 subjects were enrolled in Module 3
| Age, Continuous(years) | Placebo | Module 3 (210 mg Bolus) Original | Module 3 (420 mg Bolus) Original | Module 3 (210 mg) Lyophilized | Total |
|---|---|---|---|---|---|
| Mean | 33.7 ± 5.59 | 33.2 ± 8.30 | 32.5 ± 5.09 | 35.7 ± 8.66 | 33.7 ± 6.60 |
| Sex: Female, Male(Participants) | Placebo | Module 3 (210 mg Bolus) Original | Module 3 (420 mg Bolus) Original | Module 3 (210 mg) Lyophilized | Total |
|---|---|---|---|---|---|
| Female | 5 | 2 | 0 | 3 | 10 |
| Male | 4 | 4 | 6 | 3 | 17 |
The record gives a start of Dec 2012, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PRT064445 · Enoxaparin